PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Stanozolol Suspension for Injection (100 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid ($17\alpha$-alkylated Dihydrotestosterone derivative / Aqueous Suspension)
Stanozolol 100 mg/ml by Bioniche Pharma is an injectable anabolic agent featuring a micro-crystalline aqueous suspension of $17\alpha$-alkylated dihydrotestosterone (DHT) derivative. Formulated by Bioniche Pharma to deliver rapid systemic absorption without esterification, it promotes non-estrogenic anabolic activity, enhanced cellular nitrogen retention, and structural protein accumulation.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Stanozolol acts via direct binding to nuclear androgen receptors, driving skeletal muscle tissue synthesis and inhibiting catabolic breakdown pathways. Because it is non-aromatizable, Bioniche Pharma Stanozolol carries no inherent risk of conversion into estrogen, effectively preventing estrogenic fluid retention and gynecomastia while favorably influencing C1 esterase inhibitor levels in clinical settings.
INDICATIONS & CLINICAL USE
- Prophylactic management and symptom control in hereditary or acquired angioedema.
- Palliative support for advanced, hormone-responsive breast carcinoma in postmenopausal females.
- Therapeutic intervention to support bone matrix formation and mineral retention in severe osteoporosis under medical supervision.
CONTRAINDICATIONS
- Male patients with confirmed or suspected carcinoma of the breast or prostate gland.
- Female breast carcinoma complicated by severe hypercalcemia (elevated blood calcium levels).
- Severe renal dysfunction, nephrosis, or advanced primary liver disease.
- Pregnancy and lactation due to high risks of fetal masculinization and endocrine toxicity.
- Patients with known hypersensitivity to Stanozolol or formulation excipients in Bioniche Pharma products.
PRECAUTIONS & CLINICAL MONITORS
- Glycemic Control: Anabolic steroids may alter insulin sensitivity and peripheral glucose clearance. Diabetic patients taking Bioniche Pharma Stanozolol should perform routine glucose monitoring, as antidiabetic agents may require dose adjustments.
- Pediatric Caution: High sensitivity to androgenic agents exists in pediatric patients, requiring extreme caution due to risks of virilization and premature epiphyseal plate closure.
- Lipid Profile & Hepatic Surveillance: As an injectable $17\alpha$-alkylated formulation, continuous clinical monitoring of hepatic enzymes (AST/ALT), serum bilirubin, and serum lipid fractions (LDL elevation, HDL reduction) is strongly indicated.
ADVERSE REACTIONS
- Dermatological & Androgenic: Oily skin, acne vulgaris, facial/body hirsutism, and acceleration of male pattern baldness (androgenetic alopecia) in genetically predisposed individuals.
- Endocrine & Hepatic: Dose-dependent suppression of the hypothalamic-pituitary-gonadal (HPG) axis, transaminase elevations, and potential cholestasis upon prolonged administration.
DOSAGE & ADMINISTRATION
Because Bioniche Pharma Stanozolol for injection is an aqueous micro-crystalline suspension, thorough agitation of the vial prior to withdrawal is necessary. Administration is via deep intramuscular injection:
- Dosage Schedule: To maintain therapeutic serum concentrations, injections are typically administered 2 to 3 times per week, with total weekly dosages ranging from 200 mg to 300 mg under direct physician supervision.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place shielded from direct light exposure, heat, and ambient freezing temperatures. Keep strictly out of reach and sight of children.